MEDIROM Healthcare Technologies Overview
Valuation check: MRM's ROE is 15.55%, below the Consumer Discretionary sector average of 23.23%.
Get informed when a big investor buys or sells
+ Follow15.55%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
MEDIROM Healthcare Technologies (MRM) currently reports a ROE of 15.55%. That is below the Consumer Discretionary sector average of 23.23%. Use the charts on this page to explore MEDIROM Healthcare Technologies's ROE history and peer comparisons.
MEDIROM Healthcare Technologies's ROE of 15.55% is lower than the Consumer Discretionary sector average of 23.23%. That is roughly 33.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but MEDIROM Healthcare Technologies's current 15.55% should be judged against Consumer Discretionary norms (sector average: 23.23%) and against MRM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 15.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is 23.23%. From there, open related valuation or income-statement pages for MEDIROM Healthcare Technologies, and consider following MRM for alerts when major investors trade the stock.
MEDIROM Healthcare Technologies is classified in the Consumer Discretionary sector. On ROE, it currently shows 15.55% versus a sector average near 23.23%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing MRM with unrelated industries.
